by Cholera, an infectious disease caused by ingestion of food or water contaminated by the bacterium Vibrio cholerae, remains endemic in many developing countries. Cholera vaccines play a critical role in prevention and control of the disease by generating both mucosal and systemic immune responses.
The Global Cholera Vaccines Market is estimated to be valued at US$ 82.5 MN in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031.
Cholera Vaccines Market Demand is recommended for both domestic and international travelers to endemic areas. Currently available cholera vaccines stimulate both secretory IgA and serum IgG antibodies providing protection rates of 60% to 85% for periods of 2-3 years. Oral cholera vaccines help boost population level immunity and reduce asymptomatic carriers. The rising global awareness about cholera prevention through vaccination programs has significantly boosted the demand for oral cholera vaccines worldwide.
Key Takeaways
Key players operating in the Global Cholera Vaccines Market are Sanofi, Biovac.co.za., EMERGENT, Celldex Therapeutics, Valneva SE, Hilleman Laboratories, Shanghai United Cell Biotechnology Co., Ltd (Hillhouse Capital), PaxVax, Inc., Astellas Pharma Inc., and EUBIOLOGICS CO., LTD.
The increasing incidence of cholera outbreaks globally and growing burden of the disease especially in developing nations have augmented the demand for cholera vaccines substantially. International organizations like WHO and UNICEF are sponsoring large scale vaccination programs in endemic regions to curb transmission and reduce the burden of cholera.
Several pharmaceutical players are focusing on expanding their geographical presence across emerging markets through partnerships with local governments and non-profit organizations. Industry participants are also collaborating with UN agencies on R&D initiatives and donation commitments to strengthen immunization programs.
Market key trends
The growing focus on introducing oral cholera vaccines into routine immunization programs across high burden regions has been a major trend shaping the global cholera vaccine market. Health authorities are emphasizing on integrating cholera immunization with other EPI vaccines to achieve higher and sustainable population coverage. Recent positive additions of oral cholera vaccines into immunization recommendations of countries like Bangladesh and Haiti have provided further impetus to uptake. Continued innovation to develop more effective and affordable cholera vaccines formulations is another key industry trend.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as this market has high capital requirements and economies of scale due to stringent regulatory environment. However, the threat can increase due to increasing demand for cholera vaccines.
Bargaining power of buyers: The bargaining power of buyers is high due to availability of substitute treatments and vaccines. Buyers can negotiate on price and delivery terms.
Bargaining power of suppliers: The bargaining power of suppliers is moderate due to availability of various suppliers in the market. However, suppliers have differentiation in technology and quality.
Threat of new substitutes: The threat of new substitutes is low as there is no close substitute for cholera vaccines.
Competitive rivalry: The competitive rivalry is high due to presence of major players and differentiation in vaccine technologies.
Geographical Regions
Asia Pacific accounts for the major share in the global cholera vaccines market in terms of value due to high prevalence and demand from countries like India. South America is also a major market due to rising outbreaks.
The fastest growing region for cholera vaccines market is Africa due to rising government investments to control disease outbreaks and increasing accessibility of vaccines in countries. Factors like poor sanitation and lack of clean water in many regions is also driving vaccine adoption.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
